Health Technology · Pharmaceuticals: Major · NSE: BALPHARMA · data 2026-10-09

Bal Pharma Limited

Health check: Strong (6.7/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹93.06

Market cap

₹153 cr

P/E

20.6

P/B

—

ROE

7.9%

ROCE

19.2%

Debt / equity

2.03

Dividend yield

1.25%

1-year return

12.4%

52-week high

₹124.6

52-week low

₹60

Operating margin

6.7%

Growth

Revenue (last 12 months)	₹334 cr
Net profit (last 12 months)	₹7 cr
Sales growth, 3 years (yearly)	0.8%
Profit growth, 3 years (yearly)	34.7%

Chart patterns

Double bottom — forming (key level ₹93.8)

Similar companies

Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS) · Quest Laboratories Ltd. (QUESTLAB) · Parnax Lab Limited (PARNAXLAB) · Krebs Biochemicals & Industries Ltd. (KREBSBIO)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open BALPHARMA in NSE Scanner →